EP Patent

EP4520345A1 — Product

Assigned to Myneo NV · Expires 2025-03-12 · 1y expired

What this patent protects

The present invention relates to novel polypeptides, polynucleotides encoding said polypeptides, and compositions comprising said polypeptides or polynucleotides. The invention also concerns uses of said polypeptides, polynucleotides and compositions for the treatment, prevention…

USPTO Abstract

The present invention relates to novel polypeptides, polynucleotides encoding said polypeptides, and compositions comprising said polypeptides or polynucleotides. The invention also concerns uses of said polypeptides, polynucleotides and compositions for the treatment, prevention, and diagnosis of cancer, particularly colorectal cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP4520345A1
Jurisdiction
EP
Classification
Expires
2025-03-12
Drug substance claim
No
Drug product claim
No
Assignee
Myneo NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.